Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07141186
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and/or Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1/PD-L1 Antibody Therapy
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Conditions
Cervical Adenocarcinoma Cervical Cancer Cervical Cancer Metastatic Cervical Cancer Recurrent Cervical Cancer Squamous Cell
Interventions
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Updated 1 time since 2025 Last updated: Aug 25, 2025 Started: Oct 1, 2025 Primary completion: Oct 1, 2027 Completion: Oct 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Cervical Adenocarcinoma and Cervical Cancer, this trial is actively recruiting participants. The trial is conducted by Tianjin Medical University Cancer Institute and Hospital and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tianjin Medical University Cancer Institute and Hospital
Data source: Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.